Small-cap stocks underperformed the major indices for the second straight session, as several small health care names took their lumps.

Drugmaker Acusphere ( ACUS), of Watertown, Mass., lost 11% to $2.26, after agreeing to sell $20 million in stock and warrants to institutional investors under an existing shelf registration. Net proceeds are expected at around $18.7 million.

Geron ( GERN) also took a hit after failing to announce big news on its GRN163L cancer treatment. The California-based company only reported that phase I/II testing has yielded positive results in pharmacokinetics and tolerability. Shares tumbled 8.5% to $7.97.

Cyberonics ( CYBX), which makes devices for epilepsy treatment, slid 7.8% to $16.59 on disappointing financials. The Houston-based company's loss more than doubled to 42 cents a share -- 7 cents worse than the mean Street target from Thomson Financial. Revenue came in just shy of consensus.

Geron and Cyberonics pressured the Russell 2000, which was recently off 0.9%, or 7.83 points, to 825.35.

But a few other Russell 2000 components -- namely, Pier 1 Imports ( PIR), Robbins & Myers ( RBN) and Take-Two Interactive Software ( TTWO) -- jumped on analyst upgrades.

Goldman Sachs raised home-furnishings retailer Pier 1 to buy from hold, saying a turnaround might be around the corner. Ohio's Robbins, which makes equipment and systems for a variety of industries, was likewise upped to buy at KeyBanc Capital Market. And Take-Two was upgraded by both JPMorgan and Kaufman Brothers on the heels of last night's earnings report.

Pier 1, Robbins and New York-based Take-Two were all recently trading up 4.7% or more, the latter two in support of the S&P SmallCap 600. Still, the index was down 0.8% at 428.35.

Elsewhere in positive territory, VirtualScopics ( VSCP), of Rochester, N.Y., soared 24% to $1.40, after inking a five-year clinical-trials-services deal with a "leading" biotech company. Financial terms weren't disclosed.

Filtration-products maker MFRI ( MFRI) quintupled its first-quarter per-share earnings compared with the year-ago period. The company reported earnings of 15 cents a share, beating two analysts' estimates by a nickel. And Georgia's Exide Technologies ( XIDE) sharply narrowed its fiscal fourth-quarter loss to 35 cents a share. A year ago, the lead-acid-batteries maker lost $2.98 a share.

Shares of Illinois-based MFRI were leaping $3.12, or 13%, to $26.52. Exide advanced 8.1% to $8.25.

If you liked this article you might like

Lackluster Finish for U.S. Stocks

Lackluster Finish for U.S. Stocks

Stocks Continue to Waver at the Flat Line

Stocks Continue to Waver at the Flat Line

Oil Slides as Stocks Post a Mixed Showing

Oil Slides as Stocks Post a Mixed Showing

Stocks Flutter Near the Flat Line

Stocks Flutter Near the Flat Line

Wall Street Falls Amid Inflation Talk

Wall Street Falls Amid Inflation Talk